1
|
Fareh S, Nardi S, Argenziano L, Diamante A, Scala F, Mandurino C, Magnocavallo M, Poggio L, Scarano M, Gianfrancesco D, Palma F, Silvetti MS, Porcelli D, Racheli M, Montoy M, Charles P, Campari M, Valsecchi S, Lavalle C. Implantation of a novel insertable cardiac monitor: preliminary multicenter experience in Europe. J Interv Card Electrophysiol 2024:10.1007/s10840-024-01821-y. [PMID: 38755520 DOI: 10.1007/s10840-024-01821-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Accepted: 05/02/2024] [Indexed: 05/18/2024]
Abstract
BACKGROUND The LUX-Dx™ is a novel insertable cardiac monitor (ICM) introduced into the European market since October 2022. PURPOSE The aim of this investigation was to provide a comprehensive description of the ICM implantation experience in Europe during its initial year of commercial use. METHODS The system comprises an incision tool and a single-piece insertion tool pre-loaded with the small ICM. The implantation procedure involves incision, creation of a device pocket, insertion of the ICM, verification of sensing, and incision closure. Patients receive a mobile device with a preloaded App, connecting to their ICM and transmitting data to the management system. Data collected at European centers were analyzed at the time of implantation and before patient discharge. RESULTS A total of 368 implantation procedures were conducted across 23 centers. Syncope (235, 64%) and cryptogenic stroke (34, 9%) were the most frequent indications for ICM. Most procedures (338, 92%) were performed in electrophysiology laboratories. All ICMs were successfully implanted in the left parasternal region, oriented at 45° in 323 (88%) patients. Repositioning was necessary after sensing verification in 9 (2%) patients. No procedural complications were reported, with a median time from skin incision to suture of 4 min (25th-75th percentiles 2-7). At implantation, the mean R-wave amplitude was 0.39 ± 0.30 mV and the P-wave visibility was 91 ± 20%. Sensing parameters remained stable until pre-discharge and were not influenced by patient characteristics or indications. Procedural times were fast, exhibited consistency across patient groups, and improved after an initial experience with the system. Operator Operator feedback on the system was positive. Patients reported very good ease of use of the App and low levels of discomfort after implantation. CONCLUSIONS LUX-Dx™ implantation appears efficient and straightforward, with favorable post-implantation sensing values and associated with positive feedback from operators and patients.
Collapse
Affiliation(s)
- S Fareh
- Department of Cardiology, Hôpital de La Croix Rousse Et Hôpital Lyon Sud, Hospices Civils de Lyon, 103 Gd Rue de La Croix-Rousse, 69004, Lyon, France.
| | - S Nardi
- Pineta Grande" Hospital, Castel Volturno, CE, Italy
| | | | - A Diamante
- Casa Di Cura "Villa Azzurra", Siracusa, Italy
| | - F Scala
- Fatebenefratelli Hospital, Naples, Italy
| | - C Mandurino
- Santissima Annunziata" Hospital, Taranto, Italy
| | | | - L Poggio
- Ospedale Maggiore Di Lodi, Lodi, Italy
| | - M Scarano
- Madonna del Soccorso" Hospital, San Benedetto del Tronto (AP), Italy
| | | | - F Palma
- Mons. Dimiccoli" Hospital, Barletta, Italy
| | | | - D Porcelli
- San Pietro-Fatebenefratelli Hospital, Rome, Italy
| | - M Racheli
- San Pellegrino Hospital, Castiglione Delle Stiviere (MN), Italy
| | - M Montoy
- Department of Cardiology, Hôpital de La Croix Rousse Et Hôpital Lyon Sud, Hospices Civils de Lyon, 103 Gd Rue de La Croix-Rousse, 69004, Lyon, France
| | - P Charles
- Department of Cardiology, Hôpital de La Croix Rousse Et Hôpital Lyon Sud, Hospices Civils de Lyon, 103 Gd Rue de La Croix-Rousse, 69004, Lyon, France
| | - M Campari
- Boston Scientific Italia, Milan, Italy
| | | | - C Lavalle
- Department of Cardiovascular, Respiratory, NephrologicalAnesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy
| |
Collapse
|
2
|
Neiman ZM, Raitt MH, Rohrbach G, Dhruva SS. Monitoring of Remotely Reprogrammable Implantable Loop Recorders With Algorithms to Reduce False-Positive Alerts. J Am Heart Assoc 2024; 13:e032890. [PMID: 38390808 PMCID: PMC10944033 DOI: 10.1161/jaha.123.032890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 01/22/2024] [Indexed: 02/24/2024]
Abstract
BACKGROUND Implantable loop recorders (ILRs) are increasingly placed for arrhythmia detection. However, historically, ≈75% of ILR alerts are false positives, requiring significant time and effort for adjudication. The LINQII and LUX-Dx are remotely reprogrammable ILRs with dual-stage algorithms using artificial intelligence to reduce false positives, but their utility in routine clinical practice has not been studied. METHODS AND RESULTS We identified patients with the LINQII and LUX-Dx who were monitored by the Veterans Affairs National Cardiac Device Surveillance Program between March and June 2022. ILR programming was customized on the basis of implant indication. All alerts and every 90-day scheduled transmissions were manually reviewed. ILRs were remotely reprogrammed, as appropriate, after false-positive alerts or 2 consecutive same-type alerts, unless there was ongoing clinical need for that alert. Outcomes were total number of transmissions and false positives. We performed medical record review to determine if patients experienced any adverse clinical events, including hospitalization and mortality. Among 117 LINQII patients, there were 239 total alerts, 43 (18.0%) of which were false positives. Among 105 LUX-Dx patients, there were 300 total alerts, 115 (38.3%) of which were false positives. LINQIIs were reprogrammed 22 times, resulting in a decrease in median alerts/day from 0.13 to 0.03. LUX-Dx ILRs were reprogrammed 52 times, resulting in a decrease from 0.15 to 0.01 median alerts/day. There were no adverse clinical events that could have been identified by superior or earlier arrhythmia detection. CONCLUSIONS ILRs with artificial intelligence algorithms and remote reprogramming ability are associated with reduced alert burden because of higher true-positive rates than prior ILRs, without missing potentially consequential arrhythmias.
Collapse
Affiliation(s)
- Zachary M. Neiman
- University of California, San Francisco School of MedicineSan FranciscoCAUSA
| | - Merritt H. Raitt
- Portland Veterans Affairs Health Care SystemKnight Cardiovascular Institute, Oregon Health and Sciences UniversityPortlandORUSA
| | | | - Sanket S. Dhruva
- University of California, San Francisco School of MedicineSan FranciscoCAUSA
- San Francisco Veterans Affairs Medical CenterSan FranciscoCAUSA
| |
Collapse
|